CO5160265A1 - Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen . - Google Patents
Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen .Info
- Publication number
- CO5160265A1 CO5160265A1 CO99065259A CO99065259A CO5160265A1 CO 5160265 A1 CO5160265 A1 CO 5160265A1 CO 99065259 A CO99065259 A CO 99065259A CO 99065259 A CO99065259 A CO 99065259A CO 5160265 A1 CO5160265 A1 CO 5160265A1
- Authority
- CO
- Colombia
- Prior art keywords
- aminoacidos
- ribavirina
- esteres
- contain
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para tratar un paciente que padece de una infección por hepatitis C crónica, a los efectos de erradicar el HCV - RNA detectable, que comprende una terapia combinatoria, la cual emplea una cantidad terapéuticamente efectiva de un derivado de ribavirina de la fórmula I y una cantidad terapéuticamente efectiva de interferón alfa, durante un lapso que varía entre 20 y 80 semanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17405998A | 1998-10-16 | 1998-10-16 | |
US09/348,534 US6277830B1 (en) | 1998-10-16 | 1999-07-07 | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5160265A1 true CO5160265A1 (es) | 2002-05-30 |
Family
ID=22634639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99065259A CO5160265A1 (es) | 1998-10-16 | 1999-10-14 | Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen . |
Country Status (9)
Country | Link |
---|---|
US (1) | US6277830B1 (es) |
EP (1) | EP1121370A1 (es) |
KR (1) | KR20010080098A (es) |
AR (1) | AR021226A1 (es) |
AU (1) | AU1197600A (es) |
CO (1) | CO5160265A1 (es) |
PE (1) | PE20001109A1 (es) |
WO (1) | WO2000023455A1 (es) |
ZA (1) | ZA200102917B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800616B2 (en) * | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6403564B1 (en) * | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
SK8612002A3 (en) * | 1999-12-23 | 2003-03-04 | Ribapharm Inc | Compositions and methods for L-nucleosides, L-nucleotides, and their analogs |
AU2001249120A1 (en) * | 2000-03-09 | 2001-09-17 | Schering Corporation | Hiv immune adjuvant therapy |
WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
US6510314B1 (en) | 2000-09-08 | 2003-01-21 | Visteon Global Technologies, Inc. | Mixer circuit with output stage for implementation on integrated circuit |
CA2425522A1 (en) * | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
US6673775B2 (en) * | 2001-04-18 | 2004-01-06 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US20050009775A1 (en) * | 2001-06-21 | 2005-01-13 | Howes Peter David | Nucleoside compounds in hcv |
WO2003049760A1 (en) * | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
BR0312278A (pt) * | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
US20040106785A1 (en) * | 2002-07-25 | 2004-06-03 | Micrologix Biotech Inc. | Inhibitors of RNA dependent RNA polymerase and uses thereof |
SI1576138T1 (sl) | 2002-11-15 | 2017-07-31 | Idenix Pharmaceuticals Llc | 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo |
CN1742018A (zh) * | 2002-12-10 | 2006-03-01 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的核苷衍生物 |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
US20070072181A1 (en) * | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
UA83046C2 (ru) * | 2003-05-21 | 2008-06-10 | Берингер Ингельхайм Интернациональ Гмбх | Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе |
CN1835765A (zh) * | 2003-08-13 | 2006-09-20 | 霍华德·J·史密斯及同仁控股有限公司 | 治疗病毒感染的方法 |
CN1863812A (zh) * | 2003-09-11 | 2006-11-15 | 弗·哈夫曼-拉罗切有限公司 | 多晶型核苷化合物 |
JP2007505070A (ja) * | 2003-09-11 | 2007-03-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス性ヌクレオシド誘導体を製造する方法 |
RS20110578A3 (en) | 2003-10-14 | 2016-02-29 | F. Hoffmann-La Roche Ltd | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS |
US7410979B2 (en) * | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
US20060018875A1 (en) * | 2004-06-14 | 2006-01-26 | Blatt Lawrence M | Interferon compositions and methods of use thereof |
EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
CA2573346C (en) * | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US7309589B2 (en) | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
CN101203498A (zh) * | 2005-05-02 | 2008-06-18 | 里格尔药品股份有限公司 | 包括可代谢部分的杂环抗病毒化合物及其用途 |
US20090148407A1 (en) | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
DK1999129T3 (da) | 2005-10-11 | 2011-02-07 | Intermune Inc | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus |
EP1976382B1 (en) | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
JP2010510171A (ja) * | 2006-08-21 | 2010-04-02 | ユナイテッド セラピューティクス コーポレーション | ウイルス感染症の治療のための併用療法 |
JP2010502748A (ja) * | 2006-09-11 | 2010-01-28 | サザン リサーチ インスティテュート | アゾールヌクレオシド、並びに、rna/dnaウイルスポリメラーゼ阻害剤としての使用 |
WO2008052722A2 (en) * | 2006-11-02 | 2008-05-08 | Heidelberg Pharma Ag | Use of ribavirin-conjugates as an anti-viral drug |
JP2010528987A (ja) | 2007-05-03 | 2010-08-26 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
AR066528A1 (es) * | 2007-05-10 | 2009-08-26 | Array Biopharma Inc | Peptidos inhibidores de la replicacion del virus de la hepatitis c |
EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
AP2011005695A0 (en) | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
JP2012520884A (ja) | 2009-03-18 | 2012-09-10 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー | フラビウイルス科ウイルス感染症を治療する方法および組成物 |
AU2010298028A1 (en) | 2009-09-28 | 2012-04-19 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis C virus replication |
BR112012010110A2 (pt) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina |
AP2013006734A0 (en) | 2010-09-30 | 2013-02-28 | Boehringer Ingelheim Int | Combination therapy for treating HCV infection |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US9364484B2 (en) | 2011-12-06 | 2016-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating viral diseases |
WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
GB1482736A (en) | 1974-03-18 | 1977-08-10 | Icn Pharmaceuticals | 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives |
US4544741A (en) | 1982-03-29 | 1985-10-01 | Robins Roland K | Azole dinucleotide compounds and methods for their production |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
US4925930A (en) | 1988-11-02 | 1990-05-15 | Nucleic Acid Research Institute | Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates |
CA2129533A1 (en) * | 1992-02-10 | 1993-08-19 | Douglas Testa | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
GB9307043D0 (en) | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
GB9413724D0 (en) * | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
WO1997021452A2 (en) * | 1995-12-14 | 1997-06-19 | Advanced Magnetics, Inc. | Macromolecular prodrugs of nucleotide analogs |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
JP2001503767A (ja) | 1996-11-12 | 2001-03-21 | メディヴィル・アクチボラグ | ヌクレオシド |
-
1999
- 1999-07-07 US US09/348,534 patent/US6277830B1/en not_active Expired - Fee Related
- 1999-10-14 WO PCT/US1999/021450 patent/WO2000023455A1/en not_active Application Discontinuation
- 1999-10-14 KR KR1020017004566A patent/KR20010080098A/ko not_active Application Discontinuation
- 1999-10-14 EP EP99970663A patent/EP1121370A1/en not_active Withdrawn
- 1999-10-14 AU AU11976/00A patent/AU1197600A/en not_active Abandoned
- 1999-10-14 AR ARP990105207A patent/AR021226A1/es unknown
- 1999-10-14 PE PE1999001034A patent/PE20001109A1/es not_active Application Discontinuation
- 1999-10-14 CO CO99065259A patent/CO5160265A1/es unknown
-
2001
- 2001-04-09 ZA ZA200102917A patent/ZA200102917B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200102917B (en) | 2002-07-09 |
WO2000023455A1 (en) | 2000-04-27 |
AU1197600A (en) | 2000-05-08 |
WO2000023455A9 (en) | 2000-08-24 |
AR021226A1 (es) | 2002-07-03 |
KR20010080098A (ko) | 2001-08-22 |
US6277830B1 (en) | 2001-08-21 |
PE20001109A1 (es) | 2000-10-28 |
EP1121370A1 (en) | 2001-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5160265A1 (es) | Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen . | |
BR9812484A (pt) | Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c | |
ES2172288T3 (es) | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. | |
EA200100298A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5 | |
ES2196303T3 (es) | Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias. | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
CY1111153T1 (el) | Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης | |
ES2177780T3 (es) | Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau. | |
HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
ES2192839T3 (es) | Timosina beta 4 oxidada. | |
DK0696456T3 (da) | Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme | |
BR9915546A (pt) | Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica | |
GT199900015A (es) | Procedimiento para tratar la insuficiencia cardiaca | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
ES2136252T3 (es) | Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. | |
PT998287E (pt) | Utilizacao de levobupivacaina | |
GB0130677D0 (en) | Medicaments and novel compounds | |
ES2164447T3 (es) | Procedimiento de inhibicion de resorcion del hueso. | |
CO5190674A1 (es) | Tratamiento de desordenes neuroticos desordenes neuroticos | |
ATE81004T1 (de) | Laktamimide in der behandlung arzneiresistenter protozoeninjektionen. | |
AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
SE0004101D0 (sv) | New use | |
DE69924146D1 (de) | Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen | |
SE0004827D0 (sv) | Therapeutic compounds | |
ECSP993178A (es) | Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica |